National Vision (EYE)
(Delayed Data from NSDQ)
$13.98 USD
-0.42 (-2.92%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $13.98 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Price, Consensus and EPS Surprise
EYE 13.98 -0.42(-2.92%)
Will EYE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EYE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EYE
Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings?
Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?
EYE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Investors Undervaluing National Vision (EYE) Right Now?
Strength Seen in National Vision (EYE): Can Its 7.2% Jump Turn into More Strength?
EYE or SYK: Which Is the Better Value Stock Right Now?
Other News for EYE
National Vision Holdings, Inc. Announces Second Quarter 2024 Earnings Release and Conference Call
National Vision Announces Optometry Students Selected to Win $7,000 in Scholarships
AIM WINNERS & LOSERS: Ocean Harvest warns on revenue; Eagle Eye up
Eagle Eye Solutions Exceeds Financial Expectations
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary